RELATIONSHIP BETWEEN PHARMACOKINETICS AND ANTI-DRUG ANTIBODY STATUS OF ABP 501, A BIOSIMILAR CANDIDATE TO ADALIMUMAB

被引：4
|
作者：
Kaur, P. [1 ]
Chow, V. [1 ]
Zhang, N. [1 ]
Markus, R. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.4763
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0167
引用
收藏
页码：714 / 714
页数：1
相关论文
共 50 条
  • [1] EVALUATION OF MARKETED KITS FOR MEASUREMENT OF ABP 501, THE FIRST APPROVED ADALIMUMAB BIOSIMILAR, DRUG CONCENTRATION AND ANTI-DRUG ANTIBODY LEVELS IN PATIENT SERUM
    Mytych, Dan
    Manning, Marta Starcevic
    Colbert, Alexander
    Hoofring, Sarah
    Miller, Jill
    Gessner, Melissa
    Chow, Vincent
    Fanjiang, Gary
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1020 - 1020
  • [2] Immunological cross-reactivity of anti-drug antibodies to adalimumab and ABP 501
    Miller, J.
    Manning, M. Starcevic
    Wala, I.
    Wang, H.
    Krishnan, E.
    Kaliyaperumal, A.
    Zhang, N.
    Mytych, D.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S120 - S120
  • [3] Demonstration of Functional Similarity Comparing Adalimumab to Biosimilar Candidate ABP 501.
    Born, Teresa
    Velayudhan, Jyoti
    Chen, Yuhfung
    Thomas, Heather
    Pastula, Christina
    Maher, Gwen
    Brown, Ryan
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S661 - S661
  • [4] Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study
    Hanes, Vladimir
    Pan, Jean
    Mytych, Daniel T.
    Chien, David
    Chow, Vincent
    BLOOD, 2019, 134
  • [5] Establishing pharmacokinetic equivalence between adalimumab and ABP 501 in the presence of anti-drug antibodies using population PK modelling
    Doshi, S.
    Krishnan, E.
    Wang, H.
    Zhang, N.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S471 - S471
  • [6] ADALIMUMAB THERAPEUTIC DRUG MONITORING TEST VALIDATED FOR MEASURING ABP 501 BIOSIMILAR
    Begona Ruiz-Arguello, M.
    Maguregui, Ainara
    Martinez, Antonio
    Nagore, Daniel
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1663 - 1663
  • [7] Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar
    Ruiz-Arguello, M. B.
    Maguregui, A.
    Martinez, A.
    Nagore, D.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S265 - S266
  • [8] Time course of the incidence and magnitude of anti-drug antibodies to adalimumab and ABP 501 among patients on concomitant immunomodulatory therapy
    Mytych, D.
    Miller, J.
    Manning, M. Starcevic
    Wala, I.
    Wang, H.
    Zhang, N.
    Krishnan, E.
    Kaliyaperumal, A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S490 - S491
  • [9] Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
    Francois, Fabien
    Naimi, Loubna
    Roblin, Xavier
    Berger, Anne-Emmanuelle
    Paul, Stephane
    BMC IMMUNOLOGY, 2021, 22 (01)
  • [10] Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
    Fabien Francois
    Loubna Naimi
    Xavier Roblin
    Anne-Emmanuelle Berger
    Stephane Paul
    BMC Immunology, 22
12345